homocysteine has been researched along with fenofibrate in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (10.81) | 18.2507 |
| 2000's | 25 (67.57) | 29.6817 |
| 2010's | 8 (21.62) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Lorgeril, M; Lacan, P; Paillard, F; Richard, G; Salen, P | 1 |
| Landray, MJ; Martin, S; Martin, U; Townend, JN; Wheeler, DC | 1 |
| Dierkes, J; Luley, C; Westphal, S | 3 |
| Desager, JP; Devuyst, O; Goffin, E; Jamar, F | 1 |
| Bruckert, E; Chapman, MJ; Foglietti, MJ; Giral, P; Jacob, N; Turpin, G | 1 |
| Banditt, P; Dierkes, J; Kunstmann, S; Lössner, A; Luley, C; Westphal, S | 1 |
| Ceska, R; Grauová, B; Kozich, V; Melenovský, V; Stulc, T | 1 |
| Bostom, AG | 1 |
| Chan, NN; Chow, FC | 1 |
| Caussé, E; Chaput, E; Edgar, AD; Legendre, C; Pineau, T; Salvayre, R | 1 |
| Burke, V; Croft, KD; Playford, DA; Watts, GF | 1 |
| Holubec, L; Mayer, O; Pikner, R; Simon, J; Subrt, I | 1 |
| Ceska, R; Grauova, B; Haas, T; Hradec, J; Kozich, V; Krijt, J; Malik, J; Melenovsky, V; Stulc, T; Wichterle, D | 1 |
| Chasiotis, G; Elisaf, MS; Kakafika, A; Milionis, HJ; Papakostas, J; Seferiadis, K | 1 |
| Frohlich, J; Genest, J; Steiner, G | 1 |
| Bouly, M; Fruchart, JC; Giral, P; Jacob, N; Luc, G; Staels, B | 1 |
| Dobordzhginidze, LM | 1 |
| Bozic, M; Fressart, MM; Keber, I; Sebestjen, M; Simcic, S; Stegnar, M; Zegura, B | 1 |
| Ansquer, JC; Foucher, C; Rattier, S; Steiner, G; Taskinen, MR | 1 |
| Písaríková, A; Stanková, B; Tvrzická, E; Vecka, M; Zák, A; Zeman, M | 1 |
| Holubec, L; Mayer, O; Pikner, R; Simon, J; Trefil, L | 1 |
| Föger, B | 1 |
| Celinska-Lowenhoff, M; Potaczek, DP; Szczeklik, A; Undas, A | 1 |
| Vergès, B | 1 |
| Ehnholm, C; Hiukka, A; Jauhiainen, M; Keech, AC; Leinonen, E; Sundvall, J; Taskinen, MR | 1 |
| Contant, CF; Francone, OL; Gao, X; Lewin, AJ; Nguyen, TT; Terra, SG | 1 |
| Barter, PJ; Ehnholm, C; Keech, AC; Simes, RJ; Sullivan, DR; Taskinen, MR; Whiting, M; Zannino, D | 1 |
| Ansquer, JC; Brugère, L; Foucher, C | 1 |
| Bhalodia, Y; Jivani, N; Sheth, N; Vaghasiya, J | 1 |
| Badeau, R; Hiukka, A; Jauhiainen, M; Maranghi, M; Sundvall, J; Taskinen, MR | 1 |
| Sviridov, D | 1 |
| Karska-Basta, I; Kubicka-Trząska, A; Romanowska-Dixon, B; Undas, A | 1 |
| Ahn, YK; Baek, SH; Byun, YS; Cho, KI; Choi, DJ; Choi, SW; Choi, YS; Jang, Y; Jeon, DW; Kim, JY; Kim, KS; Kim, YJ; Lee, SH; Min, PK; Rha, SW | 1 |
| Chen, AF; Feng, X; Hao, Y; He, L; Hong, T; Li, F; Liu, J; Mao, J; Wang, G; Wang, X; Yu, J | 1 |
| Ehnholm, C; Herrmann, M; Keech, AC; Sullivan, DR; Veillard, AS; Whiting, MJ | 1 |
4 review(s) available for homocysteine and fenofibrate
| Article | Year |
|---|---|
The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels.
Topics: Fenofibrate; Homocysteine; Humans; Hyperhomocysteinemia; Hyperlipidemias; Hypolipidemic Agents; Niacin; Risk Factors; Simvastatin | 2004 |
[Fibrates: mechanism of action, effect on levels of lipids and risk of coronary events. II. Fenofibrate].
Topics: Adult; Aged; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofibrate; Fibrinogen; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Lipids; Male; Middle Aged; Placebos; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Triglycerides | 2004 |
Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fenofibrate; Homocysteine; Humans; Hypolipidemic Agents; Lipids; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Treatment Outcome | 2006 |
Fenofibrate, homocysteine and renal function.
Topics: Animals; Biomarkers; Creatinine; Disease Progression; Dyslipidemias; Fenofibrate; Glomerular Filtration Rate; Homocysteine; Humans; Hyperhomocysteinemia; Hypolipidemic Agents; Kidney; PPAR alpha; Renal Insufficiency; Risk Factors; Sulfhydryl Compounds | 2010 |
21 trial(s) available for homocysteine and fenofibrate
| Article | Year |
|---|---|
Lipid-lowering drugs and homocysteine.
Topics: Amino Acids; Coronary Disease; Double-Blind Method; Fenofibrate; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Simvastatin | 1999 |
Serum homocysteine increases after therapy with fenofibrate or bezafibrate.
Topics: Adult; Bezafibrate; Chromatography, High Pressure Liquid; Fenofibrate; Folic Acid; Hematinics; Homocysteine; Humans; Hyperhomocysteinemia; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Pilot Projects; Pyridoxine; Vitamin B 12 | 1999 |
Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia.
Topics: Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Chromatography, High Pressure Liquid; Cysteine; Dipeptides; Female; Fenofibrate; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides | 2001 |
Effects of fenofibrate and gemfibrozil on plasma homocysteine.
Topics: Adult; Aged; Creatinine; Cross-Over Studies; Cystatin C; Cystatins; Fenofibrate; Gemfibrozil; Homocysteine; Humans; Hypertriglyceridemia; Lipids; Male; Middle Aged | 2001 |
Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate.
Topics: Cross-Over Studies; Double-Blind Method; Fenofibrate; Folic Acid; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyridoxine; Vitamin B 12; Vitamins | 2001 |
Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy.
Topics: Arteriosclerosis; Dietary Supplements; Drug Synergism; Drug Therapy, Combination; Fenofibrate; Folic Acid; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Pilot Projects; Risk Factors | 2001 |
Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes.
Topics: Acetylcholine; Antioxidants; Apolipoprotein A-I; Area Under Curve; Blood Circulation; Blood Pressure; Bradykinin; Cholesterol, HDL; Cholesterol, LDL; Coenzymes; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Enzyme Inhibitors; F2-Isoprostanes; Female; Fenofibrate; Forearm; Glycated Hemoglobin; Homocysteine; Humans; Hypolipidemic Agents; Male; Middle Aged; Nitroprusside; omega-N-Methylarginine; Regional Blood Flow; Statistics as Topic; Systole; Treatment Outcome; Triglycerides; Ubiquinone; Vasodilator Agents | 2003 |
Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration.
Topics: Aged; Anticholesteremic Agents; Cross-Over Studies; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Folic Acid; Hematinics; Homocysteine; Humans; Hyperhomocysteinemia; Hypolipidemic Agents; Indoles; Male; Middle Aged; Prospective Studies | 2003 |
Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine.
Topics: Cholesterol; Creatinine; Cysteine; Female; Fenofibrate; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Prospective Studies; Statistics as Topic; Triglycerides; Uric Acid | 2003 |
Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia.
Topics: Analysis of Variance; Atorvastatin; Blood Glucose; Female; Fenofibrate; Heptanoic Acids; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Simvastatin; Uric Acid | 2003 |
Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus.
Topics: Aged; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Fenofibrate; Homocysteine; Humans; Hypolipidemic Agents; Male; Middle Aged | 2004 |
Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors.
Topics: Adult; Arteriosclerosis; Blood Coagulation; Blood Coagulation Factors; Body Weight; C-Reactive Protein; Cholesterol, LDL; Clofibric Acid; Cytokines; Fenofibrate; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyridines; Risk Factors | 2004 |
Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Body Mass Index; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Female; Fenofibrate; Fibrinogen; Follow-Up Studies; Glycated Hemoglobin; Homocysteine; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Incidence; Male; Middle Aged; Models, Biological; Smoking; Treatment Outcome | 2005 |
[Effect of n-3 polyunsaturated fatty acids on plasma lipid, LDL lipoperoxidation, homocysteine and inflammation indicators in diabetic dyslipidemia treated with statin + fibrate combination].
Topics: Adult; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Fenofibrate; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Inflammation Mediators; Lipid Peroxidation; Lipids; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Single-Blind Method | 2005 |
Folate co-administration improves the effectiveness of fenofibrate to decrease the lipoprotein oxidation and endothelial dysfunction surrogates.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Drug Therapy, Combination; Endothelium, Vascular; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Folic Acid; Homocysteine; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Prospective Studies; Thrombomodulin; Treatment Outcome; Triglycerides; Vitamin B Complex; von Willebrand Factor | 2006 |
The I allele of the angiotensin-converting enzyme gene polymorphism may determine an increase in homocysteine levels in fibrate-treated subjects.
Topics: Alleles; Female; Fenofibrate; Genotype; Homocysteine; Humans; Hypolipidemic Agents; Male; Middle Aged; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Simvastatin | 2006 |
Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.
Topics: Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fenofibrate; Homocysteine; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, VLDL; Male; Middle Aged; Placebos | 2007 |
Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein B-100; C-Reactive Protein; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Gemfibrozil; Homocysteine; Humans; Hypolipidemic Agents; Male; Middle Aged; PPAR alpha | 2008 |
Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate.
Topics: Apolipoprotein A-I; Apolipoprotein A-II; Australia; Biomarkers; Cholesterol, HDL; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Fenofibrate; Finland; Homocysteine; Humans; Hypolipidemic Agents; New Zealand; PPAR alpha; Treatment Outcome | 2009 |
Non-lipid effects of rosuvastatin-fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia.
Topics: Aged; Asian People; Biomarkers; Blood Glucose; Blood Urea Nitrogen; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Creatinine; Drug Combinations; Enzymes; Female; Fenofibrate; Fluorobenzenes; Hemoglobins; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Liver; Male; Middle Aged; Muscle, Skeletal; Patient Selection; Pyrimidines; Republic of Korea; Rhabdomyolysis; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2012 |
Plasma homocysteine and the risk of venous thromboembolism: insights from the FIELD study.
Topics: Biomarkers; Double-Blind Method; Female; Fenofibrate; Homocysteine; Humans; Hypolipidemic Agents; Male; Placebos; Proportional Hazards Models; Venous Thromboembolism | 2012 |
12 other study(ies) available for homocysteine and fenofibrate
| Article | Year |
|---|---|
Lipid-lowering drugs and homocysteine.
Topics: Fenofibrate; Homocysteine; Humans; Hypolipidemic Agents; Kidney Failure, Chronic; Middle Aged | 1999 |
Implication of fibrate therapy for homocysteine.
Topics: Clofibric Acid; Fenofibrate; Fibric Acids; Glomerular Filtration Rate; Homocysteine; Humans; Hypolipidemic Agents; Kidney Transplantation; Renal Plasma Flow, Effective | 1999 |
Effects of fenofibrate and gemfibrozil on plasma homocysteine.
Topics: Creatinine; Fenofibrate; Gemfibrozil; Glomerular Filtration Rate; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Reproducibility of Results | 2001 |
Effects of fenofibrate and gemfibrozil on plasma homocysteine.
Topics: Fenofibrate; Fibrinogen; Gemfibrozil; Homocysteine; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2001 |
Fenofibrate induces a selective increase of protein-bound homocysteine in rodents: a PPARalpha-mediated effect.
Topics: Animals; Fenofibrate; Homocysteine; Hypolipidemic Agents; Lipoproteins; Male; Mice; Mice, Inbred C57BL; Models, Animal; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2002 |
Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanism.
Topics: Animals; Fenofibrate; Homocysteine; Hypolipidemic Agents; Mice; Mice, Inbred C57BL; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2004 |
The FIELD study.
Topics: Diabetes Mellitus, Type 2; Fenofibrate; Homocysteine; Humans; Hypolipidemic Agents; Risk Factors; Venous Thrombosis | 2006 |
Role of fenofibrate alone and in combination with telmisartan on renal ischemia/reperfusion injury.
Topics: Acute Kidney Injury; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biomarkers; Drug Therapy, Combination; Fenofibrate; Homocysteine; Hypolipidemic Agents; Kidney; Kidney Function Tests; Male; Oxidative Stress; Rats; Rats, Wistar; Reperfusion Injury; Telmisartan | 2010 |
Macrophage cholesterol efflux to plasma and HDL in subjects with low and high homocysteine levels: a FIELD substudy.
Topics: Aged; Aryldialkylphosphatase; Cells, Cultured; Cholesterol; Cholesterol, HDL; Cohort Studies; Diabetes Mellitus, Type 2; Female; Fenofibrate; Foam Cells; High-Density Lipoproteins, Pre-beta; Homocysteine; Humans; Macrophages; Male; Middle Aged; Particle Size; Phospholipid Transfer Proteins | 2011 |
Fenofibrate, homocysteine, cholesterol efflux and primum non nocere.
Topics: Cholesterol; Cholesterol, HDL; Female; Fenofibrate; Foam Cells; Homocysteine; Humans; Male | 2011 |
Altered fibrin clot properties in patients with retinal vein occlusion.
Topics: C-Reactive Protein; Coronary Artery Disease; Female; Fenofibrate; Fibrin; Fibrinolysis; Heptanoic Acids; Homocysteine; Humans; Hypersensitivity, Immediate; Laser Coagulation; Lipoprotein(a); Male; Pyrroles; Retinal Vein; Retinal Vein Occlusion; Simvastatin; Tetrahydroisoquinolines; Thrombosis; Venous Thromboembolism; Venous Thrombosis | 2011 |
Coronary flow velocity reserve is improved by PPAR-α agonist fenofibrate in patients with hypertriglyceridemia.
Topics: Adult; Aged; Blood Flow Velocity; Chemokine CCL2; Coronary Circulation; Female; Fenofibrate; Homocysteine; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; PPAR alpha | 2013 |